se of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized controlled trial - MULTI-COV

ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP)0 个研究点目标入组 194 人开始时间: 2020年3月29日最近更新: 2021年6月7日

适应症

试验速览

暂无简介。

•- Adults (>= 18 years) admitted to the ICU;
•- Severe confirmed COVID-19 pneumonia, defined by i) a newly-appeared pulmonary parenchymal infiltrate; and ii) a positive RT-PCR (either upper or lower respiratory tract) for COVID-19 (SARS-CoV-2); iii) and admission to the ICU or intermediate care unit;
•- Informed consent or emergency procedure.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 97
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 97

•- Pregnancy and breastfeeding women ;
•- Congenital immunodeficiency;
•- HIV infection with CD4 count below 200/mm3 or unknown in the last year;
•- High-grade hematological malignancy;
•- Neutropenia (<1 leucocyte/mL or < 0.5 neutrophil/mL);
•- Immunosuppressive drugs within the previous 30 days, including anti-cancer cytotoxic chemotherapy and anti-rejection drugs for organ/bone marrow transplant;
•- Moribund patient or death expected from underlying disease during the current admission;
•- Patient deprived of liberty or under legal protection measure.

发起方

ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP)